Takayoshi, Tomofumi
Hirota, Yushi http://orcid.org/0000-0002-3035-4155
Yamamoto, Akane
Yoshimura, Kai
Nishikage, Seiji
Ueda, Mariko
Ogawa, Wataru
Article History
Received: 7 December 2023
Accepted: 2 March 2024
First Online: 25 March 2024
Declarations
:
: Yushi Hirota has received lecture fees from Eli Lilly Japan K.K., Sanofi Aventis, Abbott Japan, Terumo Co., and Sumitomo Pharma Co. Ltd.; research funding from Sumitomo Pharma Co. Ltd., Medtronic Japan Co. Ltd., and Kyowa Kirin Co. Ltd.; and a donation from Abbott Japan. Wataru Ogawa has received lecture fees from Sumitomo Pharma Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Abbott Japan, and Novo Nordisk Pharma Ltd.; research grants from Noster Inc., Nippon Boehringer Ingelheim Co. Ltd., Eli Lilly Japan K.K., Abbott Diabetes Care UK Ltd., Sumitomo Pharma Co. Ltd., and Teijin Pharma Ltd.; and donations from Kowa Co. Ltd., Novo Nordisk Pharma Ltd., Sumitomo Pharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Teijin Pharma Ltd. All remaining authors declare that they have no conflict of interest.
: 13 November 2018/ approval no180249.
: Informed consent was obtained in the form of an opt-out on the hospital.
: The ethics committee of Kobe University Graduate School of Medicine.
: N/A.